	US 12,441,709 B2
	Therapeutic compounds
Barrie Phillip Martin, Manchester (GB)
Assigned to Indivior UK Limited, Hull (GB)
Filed by INDIVIOR UK LIMITED, Hull (GB)
Filed on Jul. 25, 2023, as Appl. No. 18/225,966.
Application 17/459,598 is a division of application No. 16/860,572, filed on Apr. 28, 2020, granted, now 11,130,746, issued on Sep. 28, 2021.
Application 18/225,966 is a continuation of application No. 17/459,598, filed on Aug. 27, 2021, granted, now 11,753,398.
Application 16/860,572 is a continuation of application No. 16/073,429, granted, now 10,696,654, issued on Jun. 30, 2020, previously published as PCT/EP2017/051960, filed on Jan. 30, 2017.
Claims priority of application No. 1601703 (GB), filed on Jan. 29, 2016.
Prior Publication US 2024/0076282 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01)

CPC C07D 401/14 (2013.01)

13 Claims

1. A method of treating a disease or condition selected from substance dependence, alcohol dependence, and nicotine dependence;

said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound which is selected from:

N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl)pyrazin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide; and

N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl)pyrimidin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide;

or a pharmaceutically acceptable salt or solvate thereof.